We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Begins Safety Review of Bleeding With BI’s Pradaxa
FDA Begins Safety Review of Bleeding With BI’s Pradaxa
December 16, 2011
The FDA is reviewing postmarket reports of serious bleeding events in patients taking Boehringer Ingelheim’s blood-thinner Pradaxa just as the drug is facing increased competition with approval of Johnson & Johnson and Bayer’s Xarelto in atrial fibrillation (AF) patients.